Exercise Performance in Extreme EnvironmentsTSPRNCT06824571
Effects of Taurine Supplementation on Repetitive Sprint Performance and Exhaustion Time in College Students Under High-Temperature and High-Humidity Conditions
A study testing High-Dose Taurine Supplementation (6g), Medium-Dose Taurine Supplementation (4g) and Low-Dose Taurine Supplementation (1g) in people with Exercise Performance in Extreme Environments, run by Xiaodong Cheng at 1 site in China.
Trial summary
This study is designed to evaluate the effects of acute pre-exercise taurine supplementation at different doses on the performance of college students during exhaustive exercise and subsequent repetitive sprint (RS) activities in a high-temperature, high-humidity environment. Read more about this study
- Who is it for?
- Ages 20 to 26 daysHealthy volunteers can take part
- Conditions the study is for
- Exercise Performance in Extreme Environments
- What is being tested?
- High-Dose Taurine Supplementation (6g), Medium-Dose Taurine Supplementation (4g) and Low-Dose Taurine Supplementation (1g)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2024to 9 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 26 days
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- School students
- Aged between 18 and 28 years
- No exercise-related risk, as indicated by a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
- No taurine-based supplements consumed in the last month.
Who cannot join
- Individuals who do not meet the inclusion criteria
- Individuals with a history of cardiovascular issues, respiratory problems, or any condition that may impair exercise performance
- Participants who did not provide a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
- Participants who consumed taurine-based supplements in the month preceding the study.
Trial locations and contacts
1 site in 1 country.
China1 site
Capital University of Physical Education and Sports
Beijing, Beijing Municipality, 100191
About this study
This study is designed to evaluate the effects of acute pre-exercise taurine supplementation at different doses on the performance of college students during exhaustive exercise and subsequent repetitive sprint (RS) activities in a high-temperature, high-humidity environment. Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups: high-dose taurine (6g), medium-dose taurine (4g), low-dose taurine (1g), and placebo. Key performance metrics such as peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump height, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE) will be measured.
The objective of this study is to assess how taurine supplementation influences exercise performance under these challenging environmental conditions. This study will help to better understand taurine's potential effects on exercise performance and contribute to nutritional strategies for athletes exposed to extreme conditions.
Read the detailed description
This study is designed to evaluate the effects of taurine supplementation on exercise performance under extreme environmental conditions of high temperature and high humidity. The primary goal is to investigate whether taurine supplementation can enhance performance during exhaustive exercise and subsequent repetitive sprints (RS). Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups receiving either high-dose (6g), medium-dose (4g), low-dose (1g) taurine supplementation, or placebo.
The study will involve a protocol with exhaustive exercise followed by six repetitive sprints. Performance metrics such as peak power (PP), mean power (MP), and fatigue index (FI) will be recorded. Additionally, physiological parameters, including heart rate (HR) and blood lactate (BLA), as well as subjective measures like ratings of perceived exertion (RPE), will be monitored. A standardized measurement protocol will be used to ensure consistency and accuracy across trials.
- Being tested
- High-Dose Taurine Supplementation (6g), Medium-Dose Taurine Supplementation (4g), Low-Dose Taurine Supplementation (1g), Placebo (0g Taurine)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-Dose Taurine Supplementation (6g)Dietary supplement
Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Medium-Dose Taurine Supplementation (4g)Dietary supplement
Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Low-Dose Taurine Supplementation (1g)Dietary supplement
Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Placebo (0g Taurine)Dietary supplement
Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
| Study group | Role | What they receive |
|---|---|---|
| High-Dose Taurine Group (6g) | Experimental | Participants in this arm will receive taurine supplementation at a high dose of 6g, dissolved in water, administered 30 minutes prior to exercise.
High-Dose Taurine Supplementation (6g) Receives: Dietary Supplement: High-Dose Taurine Supplementation (6g) |
| Medium-Dose Taurine Group (4g) | Experimental | Participants in this study arm will receive a medium dose of taurine supplementation (4g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to evaluate the effects of medium-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a moderate taurine dosage compared to the high-dose and low-dose groups. Receives: Dietary Supplement: Medium-Dose Taurine Supplementation (4g) |
| Low-Dose Taurine Group (1g) | Experimental | Participants in this study arm will receive a low dose of taurine supplementation (1g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to assess the effects of low-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure multiple parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a smaller taurine dosage compared to the medium-dose and high-dose groups. Receives: Dietary Supplement: Low-Dose Taurine Supplementation (1g) |
| Placebo Group | Placebo comparator | Participants in this study arm will receive a placebo (inactive substance) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This group serves as the control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of an inactive placebo, which contains no taurine, to compare against the taurine intervention arms. Receives: Dietary Supplement: Placebo (0g Taurine) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Peak Power (Watts)
Description: Maximum power output during each of the 6 sprints, measured using a cycle ergometer.
Method of Assessment: Power output will be recorded for each sprint, and the peak value will be identified.
Measured: Measured at the end of each sprint on Day 1 and Day 7.
Change from Baseline in Mean Power (Watts)
Description: Average power output across all 6 sprints, reflecting sustained anaerobic performance.
Method of Assessment: Power output will be averaged across all sprints.
Measured: Measured after all 6 sprints on Day 1 and Day 7.
Change from Baseline in Fatigue Index (%/s)
Description: Rate of decline in power output across the sprints, representing fatigue resistance.
Method of Assessment: The decline in power output will be calculated as the difference between the first and last sprint, divided by the time interval.
Measured: Measured across all 6 sprints on Day 1 and Day 7.
Change from Baseline in Exhaustion Time (seconds or minutes)
Description: The duration participants can sustain exercise before reaching volitional exhaustion.
Method of Assessment: Time will be recorded from the start of exercise until the participant reaches exhaustion.
Measured: Measured at the point of exhaustion during exhaustive exercise on Day 1 and Day 7.
Change from Baseline in Blood Lactate Levels (mmol/L)
Description: Blood lactate levels will be measured to evaluate metabolic stress and recovery during exercise.
Method of Assessment: Blood samples will be collected at designated time points during recovery to assess lactate accumulation and clearance.
Measured: Measured at baseline (pre-exercise), immediately after exercise, and at specific recovery intervals on Day 1 and Day 7.
Secondary outcomes (1)
Change from Baseline in Ratings of Perceived Exertion (RPE)
Description: Participants' perceived physical and mental exertion will be assessed using the Borg Rating of Perceived Exertion Scale.
Method of Assessment: Participants will rate their exertion on a scale from 6 (no exertion at all) to 20 (maximal exertion).
Measured: Measured continuously during exhaustive exercise and repetitive sprint activity on Day 1 and Day 7.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2025
- Study start1 Dec 2024
- Primary completion1 Jan 2025
- Study completion9 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Exercise Performance in Extreme EnvironmentsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This study utilized a single-blind, randomized, crossover-controlled design to evaluate the effects of taurine supplementation at varying doses (6g, 4g, 1g) and placebo on exercise performance under high-temperature and high-humidity conditions. Each participant received all four interventions (high-dose, medium-dose, low-dose, and placebo) in randomized order, with a washout period between treatments to minimize carryover effects. This design allows each participant to serve as their own control, enhancing the precision of the comparisons across conditions.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xiaodong Cheng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Xiaodong Cheng, Xi'an Medical University
- Investigators
- Xiaodong Cheng, PhD, Principal investigator, Xi'an Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06824571
- Sponsor's protocol ID
- No. 2021A43
- Acronym
- TSPR
- Status last verified
- Feb 2025
- First submitted
- 22 Jan 2025
- Last updated
- 13 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The individual participant data (IPD) from this study, including anonymized performance metrics, physiological responses, and metabolic data, will be shared with other researchers upon reasonable request. Data will be provided in accordance with applicable ethical and regulatory guidelines to ensure the privacy and confidentiality of study participants. Requests for data access can be made by contacting the principal investigator, Cheng Xiaodong, at chengxiaodong@xiyi.edu.cn.
Publications
Cheng X, Lin Y, Li Z. Effects of different doses of taurine supplementation on repeated-sprint performance after exhaustive exercise in a high temperature and humidity environment. Front Nutr. 2026 May 20;13:1766546. doi: 10.3389/fnut.2026.1766546. eCollection 2026.
PubMed 42245559
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Taurine Supplementation on Repetitive Sprint Performance and Exhaustion Time in College Students Under High-Temperature and High-Humidity Conditions
- ClinicalTrials.gov ID
- NCT06824571
- Acronym / sponsor ID
- TSPR / No. 2021A43
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Xiaodong ChengUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 9 Jan 2025 (actual)
- First posted
- 13 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to evaluate the effects of acute pre-exercise taurine supplementation at different doses on the performance of college students during exhaustive exercise and subsequent repetitive sprint (RS) activities in a high-temperature, high-humidity environment. Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups: high-dose taurine (6g), medium-dose taurine (4g), low-dose taurine (1g), and placebo. Key performance metrics such as peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump height, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE) will be measured.
The objective of this study is to assess how taurine supplementation influences exercise performance under these challenging environmental conditions. This study will help to better understand taurine's potential effects on exercise performance and contribute to nutritional strategies for athletes exposed to extreme conditions.
Detailed description
This study is designed to evaluate the effects of taurine supplementation on exercise performance under extreme environmental conditions of high temperature and high humidity. The primary goal is to investigate whether taurine supplementation can enhance performance during exhaustive exercise and subsequent repetitive sprints (RS). Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups receiving either high-dose (6g), medium-dose (4g), low-dose (1g) taurine supplementation, or placebo.
The study will involve a protocol with exhaustive exercise followed by six repetitive sprints. Performance metrics such as peak power (PP), mean power (MP), and fatigue index (FI) will be recorded. Additionally, physiological parameters, including heart rate (HR) and blood lactate (BLA), as well as subjective measures like ratings of perceived exertion (RPE), will be monitored. A standardized measurement protocol will be used to ensure consistency and accuracy across trials.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- This study utilized a single-blind, randomized, crossover-controlled design to evaluate the effects of taurine supplementation at varying doses (6g, 4g, 1g) and placebo on exercise performance under high-temperature and high-humidity conditions. Each participant received all four interventions (high-dose, medium-dose, low-dose, and placebo) in randomized order, with a washout period between treatments to minimize carryover effects. This design allows each participant to serve as their own control, enhancing the precision of the comparisons across conditions.
| Arm | Type | Receives |
|---|---|---|
| High-Dose Taurine Group (6g) | Experimental | Dietary Supplement: High-Dose Taurine Supplementation (6g)Participants in this arm will receive taurine supplementation at a high dose of 6g, dissolved in water, administered 30 minutes prior to exercise. High-Dose Taurine Supplementation (6g) |
| Medium-Dose Taurine Group (4g) | Experimental | Dietary Supplement: Medium-Dose Taurine Supplementation (4g)Participants in this study arm will receive a medium dose of taurine supplementation (4g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to evaluate the effects of medium-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a moderate taurine dosage compared to the high-dose and low-dose groups. |
| Low-Dose Taurine Group (1g) | Experimental | Dietary Supplement: Low-Dose Taurine Supplementation (1g)Participants in this study arm will receive a low dose of taurine supplementation (1g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to assess the effects of low-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure multiple parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a smaller taurine dosage compared to the medium-dose and high-dose groups. |
| Placebo Group | Placebo comparator | Dietary Supplement: Placebo (0g Taurine)Participants in this study arm will receive a placebo (inactive substance) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This group serves as the control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of an inactive placebo, which contains no taurine, to compare against the taurine intervention arms. |
Who may qualify
- Ages
- 20 to 26 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- School students
- Aged between 18 and 28 years
- No exercise-related risk, as indicated by a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
- No taurine-based supplements consumed in the last month.
Key exclusion criteria (4 listed)
- Individuals who do not meet the inclusion criteria
- Individuals with a history of cardiovascular issues, respiratory problems, or any condition that may impair exercise performance
- Participants who did not provide a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
- Participants who consumed taurine-based supplements in the month preceding the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-Dose Taurine Supplementation (6g)Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. | Dietary supplement | High-Dose Taurine Group (6g) |
| Medium-Dose Taurine Supplementation (4g)Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. | Dietary supplement | Medium-Dose Taurine Group (4g) |
| Low-Dose Taurine Supplementation (1g)Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. | Dietary supplement | Low-Dose Taurine Group (1g) |
| Placebo (0g Taurine)Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. | Dietary supplement | Placebo Group |
Primary outcome
Change from Baseline in Peak Power (Watts)
Time frame: Measured at the end of each sprint on Day 1 and Day 7.
Description: Maximum power output during each of the 6 sprints, measured using a cycle ergometer. Method of Assessment: Power output will be recorded for each sprint, and the peak value will be identified.
Change from Baseline in Mean Power (Watts)
Time frame: Measured after all 6 sprints on Day 1 and Day 7.
Description: Average power output across all 6 sprints, reflecting sustained anaerobic performance. Method of Assessment: Power output will be averaged across all sprints.
Change from Baseline in Fatigue Index (%/s)
Time frame: Measured across all 6 sprints on Day 1 and Day 7.
Description: Rate of decline in power output across the sprints, representing fatigue resistance. Method of Assessment: The decline in power output will be calculated as the difference between the first and last sprint, divided by the time interval.
Change from Baseline in Exhaustion Time (seconds or minutes)
Time frame: Measured at the point of exhaustion during exhaustive exercise on Day 1 and Day 7.
Description: The duration participants can sustain exercise before reaching volitional exhaustion. Method of Assessment: Time will be recorded from the start of exercise until the participant reaches exhaustion.
Change from Baseline in Blood Lactate Levels (mmol/L)
Time frame: Measured at baseline (pre-exercise), immediately after exercise, and at specific recovery intervals on Day 1 and Day 7.
Description: Blood lactate levels will be measured to evaluate metabolic stress and recovery during exercise. Method of Assessment: Blood samples will be collected at designated time points during recovery to assess lactate accumulation and clearance.
1 secondary outcome
Change from Baseline in Ratings of Perceived Exertion (RPE)
Time frame: Measured continuously during exhaustive exercise and repetitive sprint activity on Day 1 and Day 7.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2025.
- Derived from this study: PubMed 42245559Cheng X, Lin Y, Li Z. Effects of different doses of taurine supplementation on repeated-sprint performance after exhaustive exercise in a high temperature and humidity environment. Front Nutr. 2026 May 20;13:1766546. doi: 10.3389/fnut.2026.1766546. eCollection 2026.
- Official website of the Capital University of Physical Education and Sports, where the study was conducted.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. The individual participant data (IPD) from this study, including anonymized performance metrics, physiological responses, and metabolic data, will be shared with other researchers upon reasonable request. Data will be provided in accordance with applicable ethical and regulatory guidelines to ensure the privacy and confidentiality of study participants. Requests for data access can be made by contacting the principal investigator, Cheng Xiaodong, at chengxiaodong@xiyi.edu.cn.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiaodong Cheng, PhD principal investigator
Xi'an Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-Dose Taurine Supplementation (6g), Medium-Dose Taurine Supplementation (4g) and Low-Dose Taurine Supplementation (1g) in people with Exercise Performance in Extreme Environments, run by Xiaodong Cheng at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Peak Power (Watts) (time frame: Measured at the end of each sprint on Day 1 and Day 7.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06824571, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2025.